Abstract
Purpose. To test the antitumor activity of magnetic fluid (MF) on the basis of substituted lanthanum-strontium manganite nanoparticles combined with alternating magnetic field (AMF) in experiments with transplanted tumors. Materials and Methods. MF with a size of nanoparticles of 30–40 nm in aqueous agarose solution was investigated. The ability of MF to heat tumor under AMF (300 kHz, 7.7 kA/m) was tested in vivo with rodent tumors (Guerin carcinoma, Walker-256 carcinosarcoma, and Lewis lung carcinoma (3LL)). Results. Single administration of MF into the tumor at a dose of 150 mg/kg (rats) or 200 mg/kg (mice) followed by AMF within 20–30 min (treatment was repeated 3-4-fold) has resulted in the complete regression of tumor in the 35% of rats and 57% of mice. Administration of MF alone or action of AMF alone has not resulted in tumor growth inhibition. The chemomodifying effect of nanohyperthermia was determined, in particular for cisplatinum: thermal enhancement ratio was 2.0. It was also observed that nanohyperthermia has resulted in the absence of 3LL metastases in 43% of mice. Conclusions. MF on the basis of lanthanum-strontium manganite may be considered as an effective inductor of tumor local hyperthermia.
Highlights
The hyperthermia (HT) of human malignant tumor is used in the combined antitumor therapy and demonstrates significant modifying effect that results in the improvement of patients’ survival [1,2,3]
One of the approaches to resolve this problem is a creation of magnetic fluids (MF) on the basis of ferromagnetic nanoparticles which are able to heat the tumor tissue under external alternating magnetic field (AMF), that was shown in the pioneer work of Jordan et al [4]
The ability of MF based on the synthesized nanoparticles of perovskite manganite (La1−xSrxMnO3) and water solution of agarose to be heated under AMF was evaluated as was indicated in materials and methods
Summary
The hyperthermia (HT) of human malignant tumor is used in the combined antitumor therapy and demonstrates significant modifying effect that results in the improvement of patients’ survival [1,2,3]. One of the approaches to resolve this problem is a creation of magnetic fluids (MF) on the basis of ferromagnetic nanoparticles which are able to heat the tumor tissue under external alternating magnetic field (AMF), that was shown in the pioneer work of Jordan et al [4]. The use of nanosized magnetic particles, which are able to generate heat under AMF, offers much extensive scope for the use of HT in the therapy of malignant tumors [5,6,7]. The nanoparticles of ferromagnetic materials have to meet various requirements; in particular, they must be slightly agglomerated, small sized, single-domained, excretable from the body, able to demonstrate high values of the SLP (specific loss power), and able to exhibit superparamagnetic properties that would not lead to the interaction of particles after removing the magnetic field [5, 6, 10]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
